Holen Sie sich die Stockscreener-App
5.60
17.65%
-1.20
Handel nachbörslich:
5.33
-0.27
-4.82%
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
3 Supercharged Stocks Flashing Strong Momentum Signals - Benzinga
Mizuho Cuts Price Target for BioXcel Amid Neutral Stance - StocksToTrade
Mizuho Slashes BioXcel Therapeutics’ Price Target, Citing Neutral Outlook - timothysykes.com
BioXcel Therapeutics CEO to participate in virtual fireside chat on Aug 14, 2025. - AInvest
BioXcel Therapeutics CEO Discusses AI-Driven Neuroscience Pipeline at Virtual Investor Event - Stock Titan
Bioxcel Therapeutics 2025 Q2 Earnings Widened Net Loss Amid Revenue Drop - AInvest
BioXcel Therapeutics Reports Q2 2025 Financial Results - TipRanks
Bioxcel Therapeutics Sees Significant Market Potential for BXCL501 in Treating Agitation Episodes - AInvest
BioXcel Therapeutics Surges 6.25% on $230M Volume Ranking 441st as Clinical Pipeline and Patent Expansions Bolster Investor Confidence - AInvest
BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative
BioXcel Therapeutics (BTAI): Assessing the Impact of SERENITY Trial Outcomes on At-Home Agitation Market Potential - AInvest
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel Therapeutics (BTAI) Q2 Financial Report: Wider Loss, Revenue Decrease, and Upcoming Business Updates - AInvest
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - Benzinga
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Q2 Earnings Miss Estimates, Revenue Down 89.1% Y/Y - AInvest
BioXcel Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$1.56, Revenue Misses Estimates at $120K - GuruFocus
BioXcel Therapeutics Reports Q2 2025 Financials, Topline Data Expected in August. - AInvest
BioXcel Therapeutics' Q2 2025 Earnings Disappointment: A Test of Biotech Resilience - AInvest
BioXcel Therapeutics Reports Q2 Earnings, SERENITY At-Home Trial Topline Expected in August. - AInvest
Press Release: BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - 富途牛牛
Bioxcel Therapeutics Surges 58.42% on $230M Volume Ranks 452nd in Market Activity as BXCL501 Trial Progress Fuels Investor Optimism - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity Growth Conference - AInvest
BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant - TipRanks
Bioxcel Therapeutics (BTAI.O) Surges Over 21%: A Deep Dive Into the Drivers Behind the Unusual Move - AInvest
BioXcel’s BXCL501 Study: A Potential Game-Changer for Psychomotor Agitation Treatment - TipRanks
BioXcel Highlights BXCL501’s Market Potential for Agitation - TipRanks
BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference. - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
BioXcel CEO Reveals Next-Gen AI Neuroscience Innovations at Major Growth ConferenceStrategic Updates Coming - Stock Titan
Bioxcel Therapeutics (BTAI.O) Surges 12.6% Without Fundamental Catalyst: A Technical and Order-Flow Deep Dive - AInvest
Bioxcel Therapeutics (BTAI) Surges 28% on Intraday Rally: What’s Fueling the Momentum? - AInvest
BTAI Surges 27% on Unprecedented Momentum: What’s Fueling the Biotech Breakout? - AInvest
Top Penny Stocks to Watch: Ainos, SG Blocks, and BioXcel Therapeutics - AInvest
BioXcel Therapeutics Sees Stock Surge Amid Positive Phase 3 Results in At-Home Trial - timothysykes.com
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative
BioXcel Therapeutics Anticipates Major Breakthrough with Completion of SERENITY At-Home Trial - StocksToTrade
Bioxcel Therapeutics (BTAI.O) Surges 17.17%—What’s Driving the Intraday Move? - AInvest
Bioxcel Therapeutics shares rise 4.38% premarket after publication in Frontiers in Pharmacology. - AInvest
Bioxcel Therapeutics Soars 11.11% on Positive Drug Study - AInvest
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits - TipRanks
Bioxcel Therapeutics shares rise 11.78% premarket after positive study results for BXCL501 in chronic psychiatric disorders. - AInvest
BioXcel study shows dexmedetomidine reduces stress behaviors By Investing.com - Investing.com Nigeria
BioXcel study shows dexmedetomidine reduces stress behaviors - Investing.com India
BTAI files 424B5 to sell up to $3.5M in stock via ATM program - Stock Titan
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies - GlobeNewswire
Breakthrough Study: BioXcel's BXCL501 Could Transform Treatment of Chronic Psychiatric Disorders - Stock Titan
Mizuho Securities Maintains Hold Rating for Bioxcel Therapeutics with $2.00 Price Target - AInvest
Bioxcel Therapeutics Soars 27% Intraday: What's Fueling This Biotech Surge? - AInvest
BioXcel’s Clinical Breakthrough Marks Market Anticipation - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 13.39%: What’s Behind the Unusual Intraday Move? - AInvest
3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab - AInvest
Why Did Bioxcel Therapeutics Drop 6.69%? - AInvest
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion. - AInvest
BioXcel Therapeutics, Inc.Common Stock (Nasdaq:BTAI) Stock Quote - FinancialContent
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock - Investing.com
Bioxcel Therapeutics (BTAI) Surges 29.9% on Phase 3 Trial Completion — What’s Next for the Biotech Breakout? - AInvest
BioXcel Therapeutics Stock Unveiled: Rollercoaster Insights - StocksToTrade
BioXcel Therapeutics Surges: What’s Behind the Move? - timothysykes.com
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion - TipRanks
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):